Emergent appoints Harsanyi chairman, Katkin to board; El-Hibri retires as executive chairman

Emergent BioSolutions Inc.

Zsolt Harsanyi, Ph.D., independent director since 2004, appointed non-executive chairman effective April 1, 2022.
Keith Katkin appointed Class I independent director, receives initial equity award of $375,000 in RSUs vesting over 3 years.
Founder Fuad El-Hibri retires as executive chairman; enters consulting agreement at $20,000/month (up to 20 hours) through March 2024.
Board eliminates executive chairman role; Marvin White, Jerome Hauer, Kathryn Zoon appointed chairs of audit, strategic operations, and scientific review committees.
El-Hibri's unvested equity awards continue to vest during consulting term; subject to non-compete and non-solicitation through 12 months post-termination.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Fuad El-Hibri

Executive Chairman

EBS · Emergent BioSolutions Inc.

Effective: 2022-04-01
Filed: March 23, 2022, 7:59 PM ET

Fuad El-Hibri, Founder and Executive Chairman of the Board, notified the Company of his retirement and resignation as an officer, director and employee of the Company, effective as of April 1, 2022

Appointed

Keith Katkin

Class I director

EBS · Emergent BioSolutions Inc.

Effective: 2022-04-01
Filed: March 23, 2022, 7:59 PM ET

the Board of Directors (the “Board”) of Emergent BioSolutions Inc. (the “Company”) appointed Keith Katkin as a Class I director of the Company, effective as of April 1, 2022

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Fuad El-Hibri resigned as Executive Chairman at Emergent BioSolutions Inc..

Action: resigned
Role: Executive Chairman

Exact text from the filing

Fuad El-Hibri, Founder and Executive Chairman of the Board, notified the Company of his retirement and resignation as an officer, director and employee of the Company, effective as of April 1, 2022

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Keith Katkin was appointed as Class I director at Emergent BioSolutions Inc..

Action: appointed
Role: Class I director

Exact text from the filing

the Board of Directors (the “Board”) of Emergent BioSolutions Inc. (the “Company”) appointed Keith Katkin as a Class I director of the Company, effective as of April 1, 2022

View on SEC.gov

Emergent BioSolutions Inc. filing history →

Source: SEC EDGAR

accession 0001367644-22-000051

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.